ketoconazole has been researched along with Chronic Disease in 54 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A combination of CsA and ketoconazole is effective in the treatment of chronic uveitis affecting the posterior pole." | 9.08 | Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. ( de Smet, MD; Nussenblatt, RB; Ramadan, AM, 1997) |
| "To assess the efficacy of orally administered itraconazole in the treatment of coccidioidal meningitis." | 9.06 | Itraconazole therapy for chronic coccidioidal meningitis. ( Denning, DW; Dupont, B; Stevens, DA; Tucker, RM, 1990) |
| "Itraconazole, 200 to 400 mg once daily, was administered to 49 patients with different types of aspergillosis: pulmonary aspergilloma (14 patients), chronic necrotizing pulmonary aspergillosis (14), and invasive aspergillosis (21)." | 9.06 | Itraconazole therapy in aspergillosis: study in 49 patients. ( Dupont, B, 1990) |
| "In a multicenter prospective randomized trial, the efficacy and toxicity of low-dose (400 mg/d) and high-dose (800 mg/d) oral ketoconazole were compared in 80 patients with blastomycosis and in 54 with histoplasmosis." | 9.05 | Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group. ( , 1985) |
| "Itraconazole, a new oral triazole antifungal agent, was administered in 75 courses to patients with chronic coccidioidomycosis at dosages of 50 to 400 mg/day for a median duration of 10 months." | 7.68 | Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. ( Arathoon, EG; Denning, DW; Rinaldi, MG; Stevens, DA; Tucker, RM, 1990) |
| "A patient with longstanding ankylosing spondylitis developed chronic necrotising pulmonary aspergillosis, which was successfully treated with itraconazole." | 7.67 | Chronic necrotising pulmonary aspergillosis treated with itraconazole. ( Cumming, D; Elliott, JA; Milne, LJ, 1989) |
| "Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension." | 7.67 | Arterial hypertension as a complication of prolonged ketoconazole treatment. ( Astorga, R; García-Luna, PP; Gomez-Pan, A; Leal-Cerro, A; Miranda, ML; Pereira, JL; Villar, J, 1989) |
| "Twenty-one patients with chronic pulmonary coccidioidomycosis were treated with ketoconazole." | 7.66 | Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. ( Catanzaro, A; Einstein, H; Friedman, PJ; Levine, B; Ross, JB; Schillaci, R, 1982) |
| "Ketoconazole was discontinued after 12 months of chronic therapy, but 2 weeks after discontinuation, blastomycosis recurred." | 5.28 | Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient. ( DeVeber, G; Hii, JH; Legault, L; Vas, SI, 1990) |
| "A combination of CsA and ketoconazole is effective in the treatment of chronic uveitis affecting the posterior pole." | 5.08 | Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. ( de Smet, MD; Nussenblatt, RB; Ramadan, AM, 1997) |
| "To assess the efficacy of orally administered itraconazole in the treatment of coccidioidal meningitis." | 5.06 | Itraconazole therapy for chronic coccidioidal meningitis. ( Denning, DW; Dupont, B; Stevens, DA; Tucker, RM, 1990) |
| "Itraconazole, 200 to 400 mg once daily, was administered to 49 patients with different types of aspergillosis: pulmonary aspergilloma (14 patients), chronic necrotizing pulmonary aspergillosis (14), and invasive aspergillosis (21)." | 5.06 | Itraconazole therapy in aspergillosis: study in 49 patients. ( Dupont, B, 1990) |
| "In a multicenter prospective randomized trial, the efficacy and toxicity of low-dose (400 mg/d) and high-dose (800 mg/d) oral ketoconazole were compared in 80 patients with blastomycosis and in 54 with histoplasmosis." | 5.05 | Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group. ( , 1985) |
| "It has been difficult to experimentally reproduce synergistic effects of ketoconazole on terfenadine-induced torsade de pointes." | 3.96 | Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes. ( Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A, 2020) |
| " The child underwent surgical drainage of a paravertebral abscess and administration of intravenous amphotericin B." | 3.70 | Chronic paronychia, osteomyelitis, and paravertebral abscess in a child with blastomycosis. ( Evans, T; Muñiz, AE, 2000) |
| "Itraconazole, a new oral triazole antifungal agent, was administered in 75 courses to patients with chronic coccidioidomycosis at dosages of 50 to 400 mg/day for a median duration of 10 months." | 3.68 | Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. ( Arathoon, EG; Denning, DW; Rinaldi, MG; Stevens, DA; Tucker, RM, 1990) |
| "A patient with longstanding ankylosing spondylitis developed chronic necrotising pulmonary aspergillosis, which was successfully treated with itraconazole." | 3.67 | Chronic necrotising pulmonary aspergillosis treated with itraconazole. ( Cumming, D; Elliott, JA; Milne, LJ, 1989) |
| "Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension." | 3.67 | Arterial hypertension as a complication of prolonged ketoconazole treatment. ( Astorga, R; García-Luna, PP; Gomez-Pan, A; Leal-Cerro, A; Miranda, ML; Pereira, JL; Villar, J, 1989) |
| "Twenty-one patients with chronic pulmonary coccidioidomycosis were treated with ketoconazole." | 3.66 | Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. ( Catanzaro, A; Einstein, H; Friedman, PJ; Levine, B; Ross, JB; Schillaci, R, 1982) |
| " Subjects were evaluated at baseline and at weeks 4, 8, 16, 26, 39, and 52 (or early termination [ET]) for adverse events (AEs), serious AEs (SAEs), target lesion erythema, scaling, and pruritus, as well as Investigator's Static Global Assessment (ISGA) scores." | 2.78 | Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study. ( Alió Saenz, AB; Butners, V; Draelos, ZD; Feldman, SR, 2013) |
| "The scheme of hair loss treatment, by means of preparations affecting pathogenetical mechanisms of diffuse hair loss development is offered." | 2.73 | [Effectiveness of the treatment plan for androgenetic alopecia]. ( Tsiskarishvili, NV; Tsiskarishvili, TsI, 2007) |
| " In group 2, on 57 of 3316 days (2%), fluconazole in a higher dosage was administered for treatment." | 2.67 | Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. ( Gentschew, G; Helm, EB; Just-Nübling, G; Meissner, K; Odewald, J; Staszewski, S; Stille, W, 1991) |
| "that may contribute to recurrence can be eliminated at the same time." | 2.38 | Chronic vulvovaginal candidosis: the role of oral treatment. ( Merkus, JM; Van Heusden, AM, 1990) |
| "flavus eumycetoma confirmed by isolation, molecular identification and immunohistochemical analysis." | 1.42 | Seventeen years of subcutaneous infection by Aspergillus flavus; eumycetoma confirmed by immunohistochemistry. ( Abbas, MA; Ahmed, SA; Al-Hatmi, AM; de Hoog, GS; Jouvion, G; Kolecka, A; Mahgoub, el S, 2015) |
| "Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks." | 1.34 | Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. ( Bhatnagar, P; Freund, KB; Meyerle, CB; Shah, V; Yannuzzi, LA, 2007) |
| "Paracoccidioidomycosis is an endemic fungal infection in Latin America." | 1.31 | Paracoccidioidomycosis: report of 2 cases mimicking squamous cell carcinoma. ( Meneses-García, A; Morales-de la Luz, R; Mosqueda-Taylor, A; Rivera, LM, 2002) |
| "Ketoconazole treatment of mice resulted in no positive cultures." | 1.28 | Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice. ( McCabe, R; Meagher, S; Mullins, B, 1991) |
| "Although there is no explanation for recurrence in most cases of CRCV, intermittent treatment schedules can be used to treat but not to cure these patients." | 1.28 | Chronic recurrent vaginal candidosis: easy to treat, difficult to cure. Results of intermittent treatment with a new oral antifungant. ( Merkus, JM; van Heusden, AM, 1990) |
| "Ketoconazole was discontinued after 12 months of chronic therapy, but 2 weeks after discontinuation, blastomycosis recurred." | 1.28 | Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient. ( DeVeber, G; Hii, JH; Legault, L; Vas, SI, 1990) |
| "My favourite treatment for pityriasis versicolor is propylene glycol 50% in water applied with a gauze pad twice daily for 2 weeks." | 1.27 | Current treatment of cutaneous Pityrosporum and Candida-infections. ( Faergemann, J, 1986) |
| "Ketoconazole is an affective therapeutic agent for griseofulvin-resistant dermatophytosis." | 1.26 | Ketoconazole in griseofulvin-resistant dermatophytosis. ( Hanifin, JM; Parker, F; Rich, P; Robertson, MH, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (40.74) | 18.7374 |
| 1990's | 24 (44.44) | 18.2507 |
| 2000's | 5 (9.26) | 29.6817 |
| 2010's | 2 (3.70) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Hagiwara-Nagasawa, M | 1 |
| Kambayashi, R | 1 |
| Chiba, K | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Matsumoto, A | 1 |
| Sugiyama, A | 1 |
| Ahmed, SA | 1 |
| Abbas, MA | 1 |
| Jouvion, G | 1 |
| Al-Hatmi, AM | 1 |
| de Hoog, GS | 1 |
| Kolecka, A | 1 |
| Mahgoub, el S | 1 |
| Draelos, ZD | 1 |
| Feldman, SR | 1 |
| Butners, V | 1 |
| Alió Saenz, AB | 1 |
| Meneses-García, A | 1 |
| Mosqueda-Taylor, A | 1 |
| Morales-de la Luz, R | 1 |
| Rivera, LM | 1 |
| Tsiskarishvili, NV | 1 |
| Tsiskarishvili, TsI | 1 |
| Meyerle, CB | 1 |
| Freund, KB | 1 |
| Bhatnagar, P | 1 |
| Shah, V | 1 |
| Yannuzzi, LA | 1 |
| Sobel, JD | 1 |
| Wong, ES | 1 |
| Hay, RJ | 3 |
| Clayton, YM | 3 |
| Noble, WC | 1 |
| Hoyos, GL | 1 |
| McEwen, JG | 1 |
| Brummer, E | 1 |
| Castañeda, E | 1 |
| Restrepo, A | 2 |
| Stevens, DA | 3 |
| Robertson, MH | 1 |
| Rich, P | 1 |
| Parker, F | 1 |
| Hanifin, JM | 1 |
| Ross, JB | 1 |
| Levine, B | 1 |
| Catanzaro, A | 1 |
| Einstein, H | 1 |
| Schillaci, R | 1 |
| Friedman, PJ | 1 |
| Harris, LF | 1 |
| Le Grand, MP | 1 |
| Serio, RA | 1 |
| Rutgeerts, LJ | 1 |
| Symoens, J | 1 |
| Marks, HJ | 1 |
| Boutros, HH | 1 |
| Van Winckle, RB | 1 |
| Evans, GA | 1 |
| Wasan, SM | 1 |
| Ysmail-Dahlouk, M | 1 |
| Amar Khodja, A | 1 |
| Ysmail-Dahlouk, S | 1 |
| Ait Belkacem, F | 1 |
| Graybill, JR | 2 |
| Ramadan, AM | 1 |
| Nussenblatt, RB | 1 |
| de Smet, MD | 1 |
| McDonald, JA | 1 |
| Saulsbury, FT | 1 |
| Smith, MB | 1 |
| Schnadig, VJ | 1 |
| Zaharopoulos, P | 1 |
| Van Hook, C | 1 |
| Su, WF | 1 |
| Lin, JK | 1 |
| Nieh, S | 1 |
| Muñiz, AE | 1 |
| Evans, T | 1 |
| Singhal, T | 1 |
| Bajpai, A | 1 |
| Kalra, V | 1 |
| Kabra, SK | 1 |
| Samantaray, JC | 1 |
| Satpathy, G | 1 |
| Gupta, AK | 1 |
| Lewis, MA | 1 |
| Samaranyake, LP | 1 |
| Lamey, PJ | 1 |
| Andreo, JA | 1 |
| Vivancos, F | 1 |
| Serrano, P | 1 |
| Soriano, J | 1 |
| Just-Nübling, G | 1 |
| Gentschew, G | 1 |
| Meissner, K | 1 |
| Odewald, J | 1 |
| Staszewski, S | 1 |
| Helm, EB | 1 |
| Stille, W | 1 |
| McCabe, R | 1 |
| Meagher, S | 1 |
| Mullins, B | 1 |
| Lee, JY | 1 |
| Hsu, ML | 1 |
| Merkus, JM | 2 |
| Van Heusden, AM | 2 |
| Fletcher, SM | 1 |
| Prussin, AJ | 1 |
| Tucker, RM | 2 |
| Denning, DW | 2 |
| Dupont, B | 2 |
| Naranjo, MS | 1 |
| Trujillo, M | 1 |
| Munera, MI | 1 |
| Restrepo, P | 1 |
| Gomez, I | 1 |
| Defaveri, J | 1 |
| Moore, MK | 1 |
| Midgely, G | 1 |
| Arathoon, EG | 1 |
| Rinaldi, MG | 1 |
| Malekzadeh, M | 1 |
| Overturf, GD | 1 |
| Auerbach, SB | 1 |
| Wong, L | 1 |
| Hirsch, M | 1 |
| Hii, JH | 1 |
| Legault, L | 1 |
| DeVeber, G | 1 |
| Vas, SI | 1 |
| Hiltbrand, JB | 1 |
| McGuirt, WF | 1 |
| Leshchenko, VM | 1 |
| Kukoleva, LI | 1 |
| Shirshikova, IuI | 1 |
| Rukavishnikova, VM | 1 |
| Dadiomova, VG | 1 |
| Elliott, JA | 1 |
| Milne, LJ | 1 |
| Cumming, D | 1 |
| Villard, C | 1 |
| Lacroix, C | 1 |
| Rabot, MH | 1 |
| Rovira, JC | 1 |
| Jacquemin, JL | 1 |
| Leal-Cerro, A | 1 |
| García-Luna, PP | 1 |
| Villar, J | 1 |
| Miranda, ML | 1 |
| Pereira, JL | 1 |
| Gomez-Pan, A | 1 |
| Astorga, R | 1 |
| De Beule, K | 1 |
| De Doncker, P | 1 |
| Cauwenbergh, G | 1 |
| Koster, M | 1 |
| Legendre, R | 1 |
| Blatchford, N | 1 |
| Daunas, J | 1 |
| Chwetzoff, E | 1 |
| Allen, CM | 1 |
| Rossie, KM | 1 |
| Haring, JI | 1 |
| Beck, FM | 1 |
| Jennings, FW | 1 |
| Sukolin, GI | 1 |
| Riumin, DV | 1 |
| Narzullaeva, RI | 1 |
| Arushanova, SA | 1 |
| Schütt, C | 1 |
| Westphal, HJ | 1 |
| Kaben, U | 1 |
| Goan, SR | 1 |
| Holzheidt, G | 1 |
| Nausch, M | 1 |
| Schulze, HA | 1 |
| Korányi, E | 1 |
| Török, I | 1 |
| Kottász, S | 1 |
| Brousil, E | 1 |
| Faergemann, J | 1 |
| Zlatkov, V | 1 |
| Karag'ozov, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS[NCT00703846] | Phase 4 | 498 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. For the emotional component, participants were asked to answer 10 questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Emotional Score is the sum of the 10 question scores; total score ranges from 10 to 50. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -5 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. For the functional component, participants were asked to answer 15 questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Functional Score is the sum of the 12 question scores; total score ranges from 15 to 75. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -4 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. Participants were asked to answer questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Global Score is the sum of the 30 question scores; total score ranges from 30 to 150. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -11 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. For the symptomatic component, participants were asked to answer 7 questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Symptomatic Score is the sum of the 7 question scores; total score ranges from 7 to 35. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -3 |
The median number of flare days for all participants was calculated based on data self-reported in diaries that participants kept during the study. The median number of flares for all participants was calculated based on data self-reported in diaries that participants kept during the study. A flare day is defined as a day on which flare signs and symptoms for seborrheic dermatitis (erythema, scaling, and pruritus of the target area) occurred. (NCT00703846)
Timeframe: From baseline through 52 weeks
| Intervention | flare days (Median) |
|---|---|
| Extina (Ketoconazole) 2% | 109 |
The median number of flares for all participants was calculated based on data self-reported in diaries that participants kept during the study. A flare is defined as a clinical diagnosis and presentation of seborrheic dermatitis that shows as an erythematous, thin, scaly patch with a greasy sandpaper texture that varies depending on disease severity. Flares are commonly seen on the scalp, nasal folds, eyebrows, glabella, upper eyelids, retroauricular/external ear canal, and midchest areas. (NCT00703846)
Timeframe: From baseline through 52 weeks
| Intervention | flares (Median) |
|---|---|
| Extina (Ketoconazole) 2% | 7 |
"An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, which does not necessarily have a causal relationship with the treatment. For a list of all adverse events occurring at or above a frequency threshold of 5% during the course of the study, see the table entitled Other (Non-Serious) Adverse Events." (NCT00703846)
Timeframe: From baseline through 52 weeks
| Intervention | participants (Number) |
|---|---|
| Extina (Ketoconazole) 2% | 282 |
"This seborrhoeic dermatitis-specific ISGA scale (range=0-4) is used to assess skin condition severity without considering changes over time (static). 0=clear, except for minor residual discoloration; 1-4=majority of lesions have average scaling/erythema scores of 1-4, respectively. 1=almost clear, occasional fine scale, faint erythema/barely perceptible plaque thickness; 2= mild, fine scale with light coloration/mild plaque elevation; 3=moderate, coarse scale with moderate red coloration/moderate plaque thickness; 4=severe, thick tenacious scale with deep coloration/severe plaque thickness." (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -1 | -2 | -2 | -2 | -2 | -2 |
Mean change from baseline was calculated as the Week 4, 8, 16, 26, 39, and 52 (or early termination) value minus the baseline value. The grading scale for erythema ranges from 0 to 4; 0=Normal skin without erythema; may have residual hyper/hypopigmentation; 1=Faint erythema; may have residual hyper/hypopigmentation; 2=Light red erythema; may have residual hyper/hypopigmentation; 3=Moderate red coloration; 4=Dusky to deep red coloration. Erythema was defined as redness of the skin caused by increased blood circulation in the capillaries found in the deeper layers of the skin. (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -2 | -2 | -2 | -2 | -2 | -2 |
Mean change from baseline was calculated as the Week 4, 8, 16, 26, 39, and 52 (or Early Termination) value minus the baseline value. The grading scale for pruritis ranges from 0 to 4; 0=No itching; 1=Minimal: rarely aware of itching; 2=Mild: only aware of itching at times; only present when relaxing; not present when focused on other activities; 3=Moderate: often aware of itching; annoying; sometimes disturbs sleep and daytime activities; 4=Severe: constant itching; distressing; frequent sleep disturbance; interferes with activities. Pruritus is defined as an itching/scratching sensation. (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -2 | -2 | -2 | -2 | -2 | -2 |
Mean change from baseline in skin assessments for scaling was calculated as the Week 4, 8, 16, 26, 39, and 52 (or Early Termination) value minus the baseline value. The grading scale for scaling ranges from 0 to 4; 0=Normal skin with rare fine scale; 1=Minimal: occasional fine scales over less than 10% of the lesions; 2=Mild: fine scales predominate; 3=Moderate: coarse scales predominate; 4=Severe: thick tenacious scales predominate. Scaling of skin is the loss of the outer layer of the epidermis in large, scale-like flakes. (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -2 | -2 | -2 | -2 | -2 | -2 |
5 reviews available for ketoconazole and Chronic Disease
| Article | Year |
|---|---|
Treatment of coccidioidomycosis.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Chronic Dis | 1993 |
Diagnosis and treatment of oral candidosis.
Topics: Antifungal Agents; Candidiasis, Oral; Chronic Disease; Fluconazole; HIV Infections; Humans; Immune T | 1991 |
Tinea capitis in adults in southern Taiwan.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Chronic Disease; Female; Griseofulvin | 1991 |
Chronic vulvovaginal candidosis: the role of oral treatment.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Female; Humans; | 1990 |
Oropharyngeal histoplasmosis.
Topics: Adult; Amphotericin B; Child; Chronic Disease; Diagnosis, Differential; Histoplasmosis; Humans; Infa | 1990 |
8 trials available for ketoconazole and Chronic Disease
| Article | Year |
|---|---|
Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antifungal Agents; Child; Chronic Disease; | 2013 |
[Effectiveness of the treatment plan for androgenetic alopecia].
Topics: Adolescent; Adult; Alopecia; Antifungal Agents; Chronic Disease; Enzyme Inhibitors; Female; Finaster | 2007 |
Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole.
Topics: Adult; Anti-Inflammatory Agents; Chronic Disease; Cyclosporine; Double-Blind Method; Drug Therapy, C | 1997 |
Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients.
Topics: Acquired Immunodeficiency Syndrome; Candidiasis, Oral; Chronic Disease; Drug Administration Schedule | 1991 |
Itraconazole therapy for chronic coccidioidal meningitis.
Topics: Adolescent; Adult; Aged; Antibodies, Fungal; Antifungal Agents; Chronic Disease; Coccidioidomycosis; | 1990 |
Itraconazole therapy in aspergillosis: study in 49 patients.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Chronic Disease; Drug Administration Schedule; Enceph | 1990 |
The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987).
Topics: Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Chronic Disease; Clinical Trials as Topic; | 1988 |
Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Topics: Adult; Aged; Blastomycosis; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, D | 1985 |
41 other studies available for ketoconazole and Chronic Disease
| Article | Year |
|---|---|
Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes.
Topics: Animals; Atrioventricular Block; Chronic Disease; Disease Models, Animal; Drug Synergism; Ketoconazo | 2020 |
Seventeen years of subcutaneous infection by Aspergillus flavus; eumycetoma confirmed by immunohistochemistry.
Topics: Antifungal Agents; Aspergillosis; Aspergillus flavus; Chronic Disease; Delayed Diagnosis; Diagnostic | 2015 |
Paracoccidioidomycosis: report of 2 cases mimicking squamous cell carcinoma.
Topics: Antifungal Agents; Carcinoma, Squamous Cell; Chronic Disease; Diagnosis, Differential; Humans; Itrac | 2002 |
Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy.
Topics: Administration, Oral; Adult; Choroid Diseases; Chronic Disease; Fluorescein Angiography; Hormone Ant | 2007 |
Vulvovaginal candidiasis--what we do and do not know.
Topics: Candidiasis, Vulvovaginal; Chronic Disease; Female; Humans; Ketoconazole; Recurrence | 1984 |
Comparison of the therapeutic effect of ketoconazole tablets and econazole lotion in the treatment of chronic paronychia.
Topics: Adult; Aged; Candida; Chronic Disease; Econazole; Female; Humans; Imidazoles; Ketoconazole; Male; Mi | 1984 |
Chronic murine paracoccidioidomycosis: effect of ketoconazole on clearance of Paracoccidioides brasiliensis and immune response.
Topics: Animals; Antibodies, Fungal; Chronic Disease; Disease Models, Animal; Fungi; Hypersensitivity, Delay | 1984 |
Ketoconazole in griseofulvin-resistant dermatophytosis.
Topics: Adult; Antifungal Agents; Chronic Disease; Dermatomycoses; Drug Resistance; Follow-Up Studies; Grise | 1982 |
Ketoconazole for treatment of chronic pulmonary coccidioidomycosis.
Topics: Adult; Aged; Antifungal Agents; Chronic Disease; Coccidioidomycosis; Female; Humans; Imidazoles; Ket | 1982 |
Histoplasmosis in Huntsville, Alabama.
Topics: Acute Disease; Adolescent; Adult; Aged; Alabama; Amphotericin B; Bone Diseases; Chronic Disease; His | 1982 |
Successful treatment of chronic esophageal candidosis with oral ketoconazole.
Topics: Administration, Oral; Aged; Antifungal Agents; Candidiasis; Chronic Disease; Esophageal Diseases; Hu | 1982 |
Treatment of chronic dermatophyte infections. The use of ketoconazole in griseofulvin treatment failures.
Topics: Adolescent; Adult; Antifungal Agents; Chronic Disease; Dermatomycoses; Female; Griseofulvin; Humans; | 1982 |
[Oral treatment of chronic recurring vaginal candidiasis with Nizoral].
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Drug Evaluation; F | 1983 |
Oral histoplasmosis masquerading as an invasive carcinoma.
Topics: Aged; Amphotericin B; Chronic Disease; Diagnosis, Differential; Female; Histoplasmosis; Humans; Keto | 1995 |
[Lupoid leishmaniasis].
Topics: Adolescent; Chronic Disease; Diagnosis, Differential; Facial Dermatoses; Female; Humans; Infant; Ket | 1994 |
Chronic Candida albicans otitis media in children with immunodeficiency.
Topics: Antifungal Agents; Candidiasis; Child; Child, Preschool; Chronic Disease; Diagnosis, Differential; F | 1997 |
Disseminated Histoplasma capsulatum infection presenting as genital ulcerations.
Topics: Antifungal Agents; Chronic Disease; Female; Histoplasmosis; Humans; Ketoconazole; Middle Aged; Papan | 1997 |
Entomophthora coronata infection of the paranasal sinuses: report of a case.
Topics: Administration, Oral; Adult; Antifungal Agents; Chronic Disease; Entomophthora; Ethmoid Sinusitis; F | 1997 |
Chronic paronychia, osteomyelitis, and paravertebral abscess in a child with blastomycosis.
Topics: Abscess; Amphotericin B; Antifungal Agents; Blastomycosis; Child; Chronic Disease; Humans; Ketoconaz | 2000 |
Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials.
Topics: Acanthamoeba; Administration, Oral; Amebiasis; Animals; Anti-Infective Agents; Antifungal Agents; Ch | 2001 |
[Visceral leishmaniasis with partial response to ketoconazole in a patient with positive antibodies to the human immunodeficiency virus].
Topics: Adult; Chronic Disease; HIV Infections; HIV Seropositivity; HIV-1; Humans; Ketoconazole; Leishmanias | 1991 |
Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice.
Topics: Acute Disease; Animals; Chagas Disease; Chronic Disease; Cyclosporins; Interferon-gamma; Ketoconazol | 1991 |
Histoplasmosis of the larynx treated with ketoconazole: a case report.
Topics: Chronic Disease; Histoplasmosis; Humans; Ketoconazole; Laryngeal Diseases; Laryngoscopy; Male; Middl | 1990 |
Chronic recurrent vaginal candidosis: easy to treat, difficult to cure. Results of intermittent treatment with a new oral antifungant.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Drug Adm | 1990 |
Treatment of paracoccidioidomycosis with itraconazole.
Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Child; Chronic Disease; Humans; Itraconaz | 1990 |
Treatment of chronic murine chromoblastomycosis with the triazole SCH39304.
Topics: Animals; Antifungal Agents; Chromoblastomycosis; Chronic Disease; Disease Models, Animal; Female; It | 1990 |
Itraconazole in the management of chronic dermatophytosis.
Topics: Adult; Aged; Antifungal Agents; Chronic Disease; Dermatomycoses; Drug Administration Schedule; Femal | 1990 |
Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Chronic Disease; Coccidioides; Coccidioidomycosis; Drug | 1990 |
Chronic, recurrent osteomyelitis caused by Scedosporium inflatum.
Topics: Child; Chronic Disease; Debridement; Drainage; Foot Diseases; Humans; Ketoconazole; Male; Mitosporic | 1990 |
Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient.
Topics: Aged; Blastomycosis; Chronic Disease; Dermatomycoses; Humans; Ketoconazole; Kidney Transplantation; | 1990 |
[Experience in treating patients with rubrophytosis with nizoral].
Topics: Adolescent; Adult; Aged; Chronic Disease; Drug Evaluation; Female; Foot Dermatoses; Hand Dermatoses; | 1989 |
Chronic necrotising pulmonary aspergillosis treated with itraconazole.
Topics: Antifungal Agents; Aspergillosis; Chronic Disease; Humans; Itraconazole; Ketoconazole; Lung; Lung Di | 1989 |
[Severe Aspergillus keratomycosis treated with itraconazole per os].
Topics: Administration, Oral; Adult; Anterior Chamber; Antifungal Agents; Aspergillosis; Aspergillus fumigat | 1989 |
Arterial hypertension as a complication of prolonged ketoconazole treatment.
Topics: Adolescent; Adult; Chronic Disease; Cushing Syndrome; Female; Humans; Hypertension; Ketoconazole; Ma | 1989 |
Resolution of candidal lesions of the dorsal rat tongue by ketoconazole.
Topics: Animals; Candidiasis, Oral; Chronic Disease; Epithelium; Female; Fibrosis; Ketoconazole; Rats; Rats, | 1988 |
Chemotherapy of chronic trypanosomiasis: the failure of ketoconazole to cure murine infections of Trypanosoma brucei with central nervous system involvement.
Topics: Animals; Central Nervous System Diseases; Chronic Disease; Drug Therapy, Combination; Ketoconazole; | 1988 |
[A case of chronic generalized granulomatous candidiasis].
Topics: Candidiasis, Cutaneous; Candidiasis, Oral; Child; Chronic Disease; Drug Therapy, Combination; Humans | 1988 |
[Effects of ketoconazole on the immune system. III. In vitro testing of ketoconazole and therapy follow-up in chronic dermatophytoses].
Topics: Adult; Chronic Disease; Dermatomycoses; Female; Follow-Up Studies; Humans; Immune System; Ketoconazo | 1988 |
Treatment of blastomycetes induced chronic prostatitis with ketoconazole (Nizoral).
Topics: Adult; Candidiasis; Chronic Disease; Humans; Ketoconazole; Male; Middle Aged; Prostatitis | 1987 |
Current treatment of cutaneous Pityrosporum and Candida-infections.
Topics: Adrenal Cortex Hormones; Candidiasis, Cutaneous; Chronic Disease; Diabetes Complications; Humans; Im | 1986 |
[Initial impressions from using the new oral antimycotic Nizoral].
Topics: Administration, Oral; Candidiasis, Vulvovaginal; Chronic Disease; Drug Evaluation; Female; Humans; K | 1987 |